30 startups | 12 are entering clinical stage of development now
1 with published clinical data.
Heart & Cardiovascular
Team that developed leading cardiovascular stent graft, first percutaneous heart valve and first heart stem cell therapy has developed 8 cardiovascular and heart-related organ regeneration startups. Second Heart Assist expects is set to complete first-in-man study in up to 30 pts by early summer and to exit by the end of the year. Only competitor on USA market now is at a $12 billion valuation. Vascustim is entering new clinical studies for diabetic ulcer treatment following pilot studies in Mexico. PressureStim is planning clinical studies for blood pressure management in Asia. AortaCell is ready to launch aorta regeneration large animal studies at U Virginia – core team previously captured world leadership in endovascular aorta repair. BioLeonhardt completed a small animal study at U of Utah and is now moving to large animal studies at Texas Heart Institute for total heart regeneration.
Major Organ Regeneration
12 startups focused on major organ regeneration. OrthoStim is entering clinical studies for knee and joint recovery. BladderCell is entering clinical studies in Brazil and has initiated a collaboration with independent group that already complete a successful study in children also in Brazil. The incontinence market is valued at over $4 billion with no full recovery solutions at this time. EyeCell completed a grant supported eye regeneration animal study in Utah and working with Dr. Laurie Chaikin and Dr. Ed Kondrot has data published on more than 176 patents. LiverCell is preparing for animal studies. KidneyCell working with collaborators in Brazil has a 21 patient clinical study published and is planing a new study. The other startups are in development stage. BioLeonhardt Whole Body is designing a whole body regeneration chamber, a womb for adults, and is filing a National Science Foundation Small Business Innovation Research grant application.
Cosmetic & Personal Care
7 startups all at clinical stage of development. MyoStim ED published first study this summer with 85% success compared to 0% for placebo group in treating erectile dysfunction. A 2nd study was published with 23 patients post surgical prostrate removal with success rates up to 50%. A new ED study with more signals is completed enrollment in May with target of 100% in target treatment group. HairCell launched clinical trials in South Africa targeting 30% improvement of hair density. Samumed a San Diego based competitor reached $12 billion valuation for 10% hair density improvement. TestiStim has patent issued and pilot data for testosterone management. SkinStim launched clinical trials in the South Africa and is preparing to launch at additional sites. DentaCell has data from numerous centers and is developing a full product pipeline. OrthodontiCell believes it can reduce time for straightening teeth by 2/3rds and keep teeth straight after straightening and his clinical trials now. Align Technology the leading competitor reached $30.9 billion valuation last year. Orthodonticell has enrolled 37 patients in its pilot clinical trial so far and expects data ready for publication by the end of fall 2019. Stem Cell Bra is launching clinical trials in South Africa after achieving 20% to 30% breast fullness volume increase in 4 weeks of treatment in 15 large animals.
CerebraCell is preparing for non-invasive clinical studies for brain injury recovery and memory improvement.
CancerCell is entering animal studies for bioelectric cancer treatment at UCLA. 140 patent claims are issued via Schuler patent option and 20 more pending from direct Leonhardt et al. filings. Patents for reading cancer tumors and custom delivering therapies. Pulse Biosciences and Novocure recently reached $500 million and $4.3 billion valuations respectively with their bioelectric cancer therapies after publishing positive pilot clinical study results. Autemedical from Brazil has also published positive clinical data for electromagenetic field cancer therapies which helps build excitement for this direction.
Estimated Startups Ripe for Strategic Acquisition Outreach Schedule
Leonhardt’s Launchpads 2020 Portfolio Class Current as of April 1, 2020 CEO Ranking
(very highly subject to change)
Note – Ripe for beginning strategic partnership/acquisition outreach efforts is defined as having completed at least a pilot first in human feasibility study in at least 5 patients, preferably more, demonstrating reasonable trends towards efficacy and safety. The startup or Licensable Technology Platform should have also filed a number of patent claims, or licensed or optioned them, as well by this stage preferably with some U.S. issued patent claims.
$15 million Use of Proceeds
Permits public advertising – limited to verified sophisticated accredited investors with experience in biotech or medtech investments
Read all risk warnings – early stage developments in highest risk category for total loss
- About $3,000,000 PRE-CLINICAL to get all 30 products patented, developed and through animal studies
- About $11,750,000 CLINICAL to get all 30 product innovations through first-in-human studies of about 10 to 30 patients each which leaves prime ripe for potential strategic partnership opportunity
- Heart & Cardiovascular (8) = $4,000,000
- Brain (4) = $1,000,000
- Cosmetic & Personal Care (7) = $2,000,000
- Major Organ Regeneration (10) = $2,000,000
- Cancer (1) = $1,000,000
- Regenerative Economy Maintenance or Other (3) = $250,000
- Loan and interest payments debt = $2,000,000+ interest
- Offering Cost and General Overhead Expenses = $1,500,000+ (may cost more)
- Reserve for Additional Potential General Overhead Increases and Other Purposes = $1,250,000
2020 Published Goals in Annual Report and on Web Site – Click Here
2020 Portfolio and Development Pipeline – Click Here
2020 Annual Report – Click Here
Business model = accelerate 6 startups each year through first-in-man results and opportunity to seek strategic partner/buyer each year for the next 5 years. Goal is 23X ROI on accelerator shares and 63X on individual startup shares after 5 years.
Investment into the accelerator is 2:1 meaning if an investor invests $30,000 they get $30,000 worth of accelerator shares and also at no additional charge warrant to acquire by Dec. 31 of the year they invested also $30,000 worth of individual startup shares within the accelerator of their choice. They can choose to allocate $1000 each in 30 startups by example, $10,000 each in three startups or all $30,000 of their warrant into their single favorite startup.
Note – By charter we are limited to 30 startups in our accelerator in any given annual portfolio class. In short durations where we may have more than 30 startups we are working towards a merger, sale or a cut to reduce back down to 30. In the case of DentaCell Accelerator we have an accelerator within the accelerator which expands the total number of startups under this sub-accelerator. We are considering merging now VibroCell assets into either Second Heart Assist, Inc. or BioLeonhardt as an example.
The Medical Device Milestone Map and Exit Data From 2000 to Now on 331 Deals
Medtech Exits Valuations
< $50 million = 24% > $50 to $150 million = 28%
> 150 million to $250 million = 10%
> $250 million to $350 million 7%
> $350 million to $500 million 6%
> $500 million + = 4%
Timeline To Exit
Under 2 years = 2%
2 to 4 years = 7%
4 to 6 years = 16%
6 to 8 years = 22%
8 to 10 years = 22%
10 to 12 = 13%
12 to 14 years = 8%
14 to 16 years = 5%
16 years + = 4%
Revenues at Exit
Pre-revenue $0 = 28%
< $10 milllion = 6%
$10 to $25 million = 8%
$25 to $50 million = 7%
$50 million+ = 3.5%
$100 million = 2.5%
Unknown = 47%
Warning: Investment in our innovation and startup accelerator must be viewed as very high risk for loss. We are attempting to develop organ regeneration technologies where others with far more substantial resources have failed. Our developments are all very early stage. Despite some early data our technologies cannot be considered to be proven to be either safe or effective. Our patents issued, optioned or licensed may not be maintained. Our patents pending may not be issued. We may be found to infringe on others patents. We are developing more than 30 innovations which spreads our small staff thin. We are highly dependent on outside supplier and consultants. Any timelines quoted may take substantially longer by many years. Most, if not all, our team members derive income from other sources which may limit their focus on our accelerator and its startups. The company lacks sufficient resources at this time in all forms to complete development of its products. This investment is only suitable to accredited highly experienced investors with substantial knowledge of the healthcare industry and the risk associated with medical device and biotech startups and their product developments that are prepared to lose their entire investment without incurring financial hardship. Information about the status of our many projects is subject to change often. With a small staff we are not able to keep all web site pages up to date at all times. Much of the information on many of our thousands of web site pages requires updating. If you have any questions please email us at email@example.com
Any financial projections given are illustrative only and none of the projections or assumptions should be taken as promises on the part of the Company nor should they be taken as implying any indication, assurance or guarantee that those assumptions are correct or exhaustive.
These pitches contain forward-looking statements. These statements relate to, amongst other things, the Company’s future prospects, developments and business strategies. Forward-looking statements are identified by their use of terms and phrases such as “believe”, “could”, “envisage”, “estimate”, “intend”, “may”, “plan”, “will” or the negative of those, variations or comparable expressions, including references to assumptions.
The forward-looking statements in this Pitch are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. If one or more of these risks or uncertainties materialises , or if underlying assumptions prove incorrect, the Company’s actual results may vary materially from those expected, estimated or projected. Given these risks and uncertainties, potential investors should not place any reliance on forward looking statements. These forward-looking statements are made only as at the date of the Pitch.
Each recipient of these Pitches must make their own independent assessment of the information provided by the Company and is recommended to seek independent advice on the contents hereof from an authorized person specializing in advising on investments of the kind in question. Neither the Company, Leonhardt’s Launchpads, nor any of their advisers, nor their respective directors, partners, representatives, agents, consultants or employees shall be liable for any direct, indirect or consequential loss or damage suffered by any person relying on statements or omissions from the Pitch and to the maximum extent permitted by law, all conditions, warranties and other terms which might be implied by statute, common law or the law of equity and any such liability are expressly excluded. The Pitch should not be construed as a recommendation to prospective investors by the Company or Leonhardt’s Launchpads, Cal-X Stars Business Accelerator, Inc., or any of their respective officers to invest in the Company, and does not form any commitment by the Company to proceed with an investment. The Company and Leonhardt’s Launchpads, Leonhardt Ventures or Cal-X Stars Business Accelerator, Inc. reserve the right to terminate the procedure at any time and to terminate any discussions and negotiations with any prospective investors at any time and without giving any reason.
Any and all discussions, negotiations and communications, including through any online forums, between any recipient of the Pitches and the Company and their respective directors, shareholders, employees, advisers and/or representatives will remain subject to contract. Any person who invests in the Company at any time must comply with all applicable laws and regulations in force in any jurisdiction in which they acquire, offer or sell shares and must obtain any consent, approval or permission required in respect of any such transaction under the laws and regulations in force in any jurisdiction to which they are subject or in which any such transaction takes place or in which they possess the Pitch. Neither the Company, Leonhardt’s Launchpads, nor any of their respective directors, partners, representatives, agents, consultants or employees shall have any responsibility for any such matters.
The distribution of the Pitches in certain jurisdictions other than California may be restricted by law and therefore persons accessing the Pitch into whose possession the Pitch documents come should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of securities laws of any such jurisdiction. Recipients represent and warrant to the Company and Leonhardt’s Launchpads, that they are able to receive the Pitches without contravention of applicable legal or regulatory restrictions in the jurisdiction in which they reside, conduct business or receive the Pitches, including in particular the requirements of the Act.
The individual startups accept highlighted in this listing of elevator pitches accept responsibility for the information contained in each Pitch. The Pitches are meant to only reflect the most positive and optimistic personal opinion of the company founders and nothing more or less. To the best of the knowledge and belief of the Company (who has taken all reasonable care to ensure that such is the case) the information contained in this Pitch is in accordance with the facts and there are by the extreme brief nature of the few line elevator pitches there are indeed facts the omission of which would affect the validity of such information. This information may be obtained elsewhere such as our private placement memorandum, our annual report or the risk and warnings disclaimers proceeding and following the elevator pitches on this page or on the individual startup web sites . These risks include in brief – patents cited may not protect us, patent license agreements may not hold up, patents pending may not be issued, company lacks resources to complete research, early data is not enough to determine definitively if technology works, all agreements are subject to conditions being met and due to lack of financial resources the likelihood and risk of not meeting such conditions is high, many agreements may not be properly ratified or signed, company is underfunded and understaffed and personnel aboard have diverted attention with other jobs and many projects.
The information contained in the Updates section and the Q&A section and any downloaded documents do not form part of the Pitch and have not been reviewed or approved by Leonhardt’s Launchpads Board of Directors or Legal Counsel. Similarly, any information published outside of the Leonhardt’s Launchpads web sites , including on social media platforms (e.g. Facebook, Twitter) or the Company’s news blog, does not form part of the Pitches. Leonhardt’s Launchpads, Leonhardt Ventures and Cal-X Stars Business Accelerator, Inc., Second Heart Assist, Inc., assumes no responsibility for information contained in the Q&A or Updates section, downloads or in any form of media outside the Leonhardt’s Launchpads accelerator and such information should not be deemed an offer or invitation to invest or be relied on to invest.
Clinical Study Enrollment Numbers and Total Clinical Data Clarification
The number of clinical study patients enrolled in studies quoted in various communications not only include the number of patients enrolled in studies that we have designed, launched, funded and supported internally with our own devices, programming or compositions but also may likely include data or enrollment numbers acquired from collaborating investigators where they have completed and published the studies before joining forces with us in one form or another. The first MyoStim ED pilot studies for bioelectric treatment of erectile dysfunction by example, that we believe followed some of our early issued (VEGF signal) patent claims, were completed and published independently by Dr. Cristiane Carboni and her colleagues before she joined forces with us to complete a number of new follow-on studies with our supplied devices and programming. In this example the data from the new studies, with our devices and our patented or patent pending bioelectric stimulation programming, were superior to the original independent pilot study results. When we quote the total number of patients enrolled in all MyoStim ED studies we include the numbers enrolled in the earlier independent pilot studies. In some more rare cases data or clinical enrollment numbers quoted or cited from studies may include those done by independent investigators that we believe followed our issued patent claims that have not formally joined forces with us in any capacity. The related scientific articles sections or pages on our web sites include data from similar studies that may support directly or in-directly the research we are doing. These enrollment numbers are not counted in our total clinical study enrollment numbers quoted. In cases where we acquire intellectual property (IP) from an outside inventor, developer or investigator and previous pre-clinical and clinical data has been gathered supporting that IP we always strive to establish as part of the agreement that all ownership rights to that data is considered part of acquisition.